Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.6K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

12.1K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of andexanet alfa: A British Society for Haematology position statement.

British journal of haematology·2026
Same author

Nanobodies to GPVI as alternative reagents for platelet spreading.

Platelets·2026
Same author

Diagnosis without consent: A reply to Johnstone et al. "De-diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria".

HemaSphere·2026
Same author

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England.

British journal of clinical pharmacology·2025
Same author

Common Themes and Uncertainties in Management of Secondary Polycythaemia: An International Clinician Survey of Practice.

EJHaem·2025
Same author

A computational framework for the investigation of phosphoinositide regulation.

PLoS computational biology·2025

Related Experiment Video

Updated: Jul 12, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.8K

PF4 activates the c-Mpl-Jak2 pathway in platelets.

Richard J Buka1, Samantha J Montague1,2, Luis A Moran1

  • 1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

Blood
|October 26, 2023
PubMed
Summary

Platelet factor 4 (PF4) activates platelets by binding to the thrombopoietin receptor (c-Mpl), initiating a signaling cascade. This discovery offers new insights into vaccine-induced immune thrombocytopenia and thrombosis (VITT) pathogenesis.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

130
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

428

Related Experiment Videos

Last Updated: Jul 12, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

130
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

428

Area of Science:

  • Immunology
  • Hematology
  • Molecular Biology

Background:

  • Platelet factor 4 (PF4) is a chemokine released from activated platelets.
  • PF4 is implicated in vaccine-induced immune thrombocytopenia and thrombosis (VITT) via antibody-PF4 immune complexes activating platelets and neutrophils.
  • The precise mechanism of PF4-mediated platelet activation in VITT remains incompletely understood.

Purpose of the Study:

  • To investigate the direct interaction of PF4 with platelet receptors.
  • To elucidate the signaling pathways activated by PF4 on platelets.
  • To determine the role of PF4-c-Mpl interaction in VITT pathogenesis.

Main Methods:

  • Investigated PF4 binding to platelet receptors using biochemical assays.
  • Analyzed downstream signaling, including JAK2/STAT activation, in response to PF4.
  • Assessed the impact of c-Mpl-JAK2 pathway inhibition on platelet aggregation induced by PF4 and VITT patient samples.

Main Results:

  • Demonstrated that PF4 directly binds and activates the thrombopoietin receptor (c-Mpl) on platelets.
  • Showed PF4-induced c-Mpl activation leads to JAK2 activation and STAT3/STAT5 phosphorylation.
  • Confirmed that inhibiting the c-Mpl-JAK2 pathway reduces platelet aggregation induced by PF4, VITT sera, and PF4-IgG complexes.

Conclusions:

  • PF4 activates platelets through a novel pathway involving direct binding to c-Mpl.
  • This PF4-c-Mpl-JAK2 axis is a critical mediator of platelet activation in VITT.
  • The findings support a dual-receptor model for PF4-immune complex-mediated platelet activation in VITT.